Treatment for dystonia in childhood

European Journal of Neurology

Volumn 19, Issue 10, 2012, Pages 1292-1299

  Roubertie, A ^a,b,c   Mariani, L L ^d   Fernandez Alvarez, E ^e   Doummar, D ^a,f   Roze, E ^a,c,d  

^a De Neurologie Pédiatrique ^*  (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HOSPITAL SANT JOAN DE DÉU   (Spain)

^f ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Anticholinergics; Botulinum toxin; Deep brain stimulation; Dystonia; Levodopa; Tetrabenazine; Therapy

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMITRIPTYLINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BROMOCRIPTINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CODEINE; DIAZEPAM; GABAPENTIN; HALOPERIDOL; LEVODOPA; LISURIDE; MEXILETINE; MIDAZOLAM; MORPHINE; MORPHINE SULFATE; PIMOZIDE; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE; SELEGILINE; TETRABENAZINE; THIOCOLCHICOSIDE; TIAPRIDE; TRANYLCYPROMINE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

AROMATIC LEVO AMINO ACID DECARBOXYLASE DEFICIENCY; ASTHENIA; ATHETOSIS; BEHAVIOR DISORDER; BLURRED VISION; BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; BRAIN MATURATION; CEREBRAL PALSY; CHILDHOOD DISEASE; CHOREA; CLINICAL EVALUATION; CLINICAL PRACTICE; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOPA RESPONSIVE DYSTONIA; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; DYSPHAGIA; DYSTONIA; DYSTONIC DISORDER; ENZYME DEFICIENCY; ERGONOMICS; GASTROINTESTINAL DISEASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE 1 DEFICIENCY; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; LIQUORRHEA; LOW DRUG DOSE; MEMORY DISORDER; NERVE CELL PLASTICITY; NERVOUSNESS; OCCUPATIONAL THERAPY; PARKINSONISM; PHYSIOTHERAPY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RASH; REVIEW; SEIZURE; SEPIAPTERIN REDUCTASE DEFICIENCY; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; SPEECH THERAPY; STATUS DYSTONICUS; SYSTEMATIC REVIEW; TIC; TYROSINE 3 MONOOXYGENASE DEFICIENCY; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VERTIGO; WEIGHT GAIN; WILSON DISEASE; WITHDRAWAL SYNDROME; XEROSTOMIA;

CHILD; DYSTONIA; DYSTONIC DISORDERS; HUMANS;

EID: 84866279295     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03649.x     Document Type: Review

References (46)

1. Shanker V, Bressman SB. What's new in dystonia? Curr Neurol Neurosci Rep 2009; 9: 278-284.
2. Vidailhet M, Grabli D, Roze E. Pathophysiology of dystonia. Curr Opin Neurol 2009; 22: 406-413.
3. Hallett M. Neurophysiology of dystonia: the role of inhibition. Neurobiol Dis 2011; 42: 177-184.
4. Roubertie A, Echenne B, Cif L, Vayssiere N, Hemm S, Coubes P. Treatment of early-onset dystonia: update and a new perspective. Childs Nerv Syst 2000; 16: 334-340.
5. Jankovic J. Treatment of dystonia. Lancet Neurol 2006; 5: 864-872.
6. Roubertie A, Rivier F, Humbertclaude V, et al. Les dystonies de l'enfant: etiologies et strategie diagnostique. Rev Neurol (Paris) 2002; 158: 413-424.
7. Fernandez-Alvarez E. Prevalence of pediatric movement disorders. In: Fernandez-Alvarez E, Arzimanoglou A, Tolosa E eds. Pediatric Movement Disorders: Progress in Understanding. Montrouge: John Libbey Eurotext, 2005: 1-18.
8. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13: 433-444.
9. Schneider SA, Bhatia KP. Secondary dystonia - clinical clues and syndromic associations. Eur J Neurol 2010; 17(Suppl. 1): 52-57.
10. Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008; 70: 1010-1016.
11. Bleton JP. Physiotherapy of focal dystonia: a physiotherapist's personal experience. Eur J Neurol 2010; 17(Suppl. 1): 107-112.
12. Flamand-Rouviere C, Guettard E, Moreau C, et al. Speech disturbances in patients with dystonia or chorea due to neurometabolic disorders. Mov Disord 2010; 25: 1605-1611.
13. Pons R. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J Inherit Metab Dis 2009; 32: 321-332.
14. Luciano MS, Ozelius L, Sims K, Raymond D, Liu L, Saunders-Pullman R. Responsiveness to levodopa in epsilon-sarcoglycan deletions. Mov Disord 2009; 24: 425-428.
15. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004; 11: 361-370.
16. Manegold C, Hoffmann GF, Degen I, et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 2009; 32: 371-380.
17. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6: 826-829.
18. Hoon AH Jr, Freese PO, Reinhardt EM, et al. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr Neurol 2001; 25: 55-58.
19. Sanger TD, Bastian A, Brunstrom J, et al. Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy. J Child Neurol 2007; 22: 530-537.
20. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992; 15: 276-288.
21. Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus 2006; 21: e3.
22. Woon K, Tsegaye M, Vloeberghs MH. The role of intrathecal baclofen in the management of primary and secondary dystonia in children. Br J Neurosurg 2007; 21: 355-358.
23. Pin TW, McCartney L, Lewis J, Waugh MC. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol 2011; 53: 885-895.
24. Mariotti P, Fasano A, Contarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007; 22: 963-968.
25. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord 2006; 21: 1966-1972.
26. Berg D, Becker G, Naumann M, Reiners K. Morphine in tardive and idiopathic dystonia (short communication). J Neural Transm 2001; 108: 1035-1041.
27. Heinen F, Molenaers G, Fairhurst C, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006; 10: 215-225.
28. Bertrand H, Forin V. Botulinum toxin type A in children: evaluation of indications with a review of the literature. Ann Readapt Med Phys 2003; 46: 346-352.
29. Guettard E, Roze E, Abada G, et al. Management of spasticity and dystonia in children with acquired brain injury with rehabilitation and botulinum toxin A. Dev Neurorehabil 2009; 12: 128-138.
30. Narayanan UG. Botulinum toxin: does the black box warning justify change in practice? Dev Med Child Neurol 2011; 53: 101-102.
31. O'Flaherty SJ, Janakan V, Morrow AM, Scheinberg AM, Waugh MC. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev Med Child Neurol 2011; 53: 125-130.
32. Borggraefe I, Mehrkens JH, Telegravciska M, Berweck S, Botzel K, Heinen F. Bilateral pallidal stimulation in children and adolescents with primary generalized dystonia - report of six patients and literature-based analysis of predictive outcomes variables. Brain Dev 2010; 32: 223-228.
33. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 2000; 355: 2220-2221.
34. Marks WA, Honeycutt J, Acosta F, Reed M. Deep brain stimulation for pediatric movement disorders. Semin Pediatr Neurol 2009; 16: 90-98.
35. Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain 2008; 131: 1895-1902.
36. Vasques X, Cif L, Gonzalez V, Nicholson C, Coubes P. Factors predicting improvement in primary generalized dystonia treated by pallidal deep brain stimulation. Mov Disord 2009; 24: 846-853.
37. Andrews C, Aviles-Olmos I, Hariz M, Foltynie T. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81: 1383-1389.
38. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3year follow-up study. Lancet Neurol 2007; 6: 223-229.
39. Isaias IU, Alterman RL, Tagliati M. Deep brain stimulation for primary generalized dystonia: long-term outcomes. Arch Neurol 2009; 66: 465-470.
40. Cif L, Vasques X, Gonzalez V, et al. Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: an open-label study. Mov Disord 2010; 25: 289-299.
41. Timmermann L, Pauls KA, Wieland K, et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010; 133: 701-712.
42. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8: 709-717.
43. Marks WA, Honeycutt J, Acosta F Jr, et al. Dystonia due to cerebral palsy responds to deep brain stimulation of the globus pallidus internus. Mov Disord 2011; 26: 1748-1751.
44. Coubes P, Cif L, Azais M, et al. Traitement des syndromes dystoniques par stimulation electrique chronique du globus pallidus interne. Arch Pediatr 2002; 9(Suppl. 2): 84s-86s.
45. Azoulay-Zyss J, Roze E, Welter ML, et al. Bilateral deep brain stimulation of the pallidum for myoclonus-dystonia due to epsilon-sarcoglycan mutations: a pilot study. Arch Neurol 2011; 68: 94-98.
46. Nardocci N, Temudo T, Echenne B, Roubertie A. Status dystonicus in children. In: Fernandez-Alvarez E, Arzimanoglou A, Tolosa E eds. Pediatric Movement Disorders: Progress in Understanding. Montrouge: John Libbey Eurotext, 2005: 71-76.